Diabetic foot infection

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
G Urology/Gynaecology (ATC G) 1
J Anti-infectives (ATC J) 1
ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Azole antifungal 1 substance
Phase III: 1 Phase I/II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Micurx Pharmaceuticals Inc. Commercial
    CONTEZOLID; LINEZOLID; METRONIDAZOLE; SODIUM O-ACETYL-(R)-ISOXAZOL-3-YL((2-OXO-3-(2,3,5-TRIFLUORO-4-(4-OXO-3,4-DIHYDROPYRIDIN-1(2H)-YL)PHENYL)OXAZOLIDIN-5-YL)METHYL)PHOSPHORAMIDATE
    2022-500257-16-00 15 countries 2023 n=644
    Recruiting

Phase I/II

1 trial
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2022-500541-24-00 1 country 2024 n=60
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Micurx Pharmaceuticals Inc. Commercial 1 Phase III 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase I/II 1
New trials by year
2023
1
2024
1
← All indication landscapes